| INTRODUCTION
Delirium and Alzheimer disease (AD) are frequent causes of cognitive impairment among older adults and share a complex relationship in that delirium and AD can occur independently, concurrently, and interactively-for example, delirium can alter the course of an underlying AD. Whether delirium is a marker of vulnerability to AD, unmasks unrecognized AD, accelerates preclinical AD, or itself can cause permanent neuronal damage and lead to AD is poorly understood, and addressing these issues is a high-priority focus in aging research. 1 In this paper, we propose a novel conceptual model ( Figure 1 ) illustrating how biomarker studies might advance our understanding of the interrelationship of delirium and AD due to neuronal injury. We cite examples of potential neuronal injury biomarkers, their temporal trends, and how they fit within the framework of our model.
| DELIRIUM, ALZHEIMER DISEASE, AND THEIR INTERRELATIONSHIP
Delirium, an acute decline in cognition and attention, is a common complication of illness, acute trauma, and surgery in older adults, and it has been associated with multiple adverse outcomes including increased morbidity and mortality, falls, decline in cognitive and physical function, and loss of independence. Accordingly, delirium results in longer hospital stays and higher costs to patients, family caregivers, and the health care system. Some patients develop long-term cognitive decline after delirium, and delirium significantly increases the risk of incident dementia. Delirium is often unrecognized or mistaken for AD.
In contrast, AD is an insidious neurodegenerative condition characterized by chronic and progressive cognitive decline. The prevalence of delirium among patients with dementia is estimated to range from 22% to 89% of hospitalized and community populations aged 65 and older. 2 When patients with AD do develop delirium, they are more likely to experience adverse outcomes including death or placement in a nursing facility and accelerated cognitive decline. 1 A number of mechanisms for how delirium may contribute to dementia have been proposed, including inflammation, oxidative stress, neuronal dysfunction, and acceleration of dementia pathology. 3 Some insults, such as hypoxia, metabolic derangements, or particular drugs (eg, anticholinergics), may directly cause neuronal dysfunction via alterations in neurotransmitters (eg, acetylcholine deficiency), 4 while others, such as inflammation, lead to activation of microglia and astrocytes and then in turn to the production of free radicals, complement factors, glutamate, and nitric oxide 5 and ultimately neuronal injury. Building on prior work examining neuroinflammation and these other potential mechanisms, biomarkers of neuronal injury provide a novel link between delirium and AD 3 which has not been fully explored.
| BIOMARKERS OF DELIRIUM AND ALZHEIMER'S DISEASE
Although not yet used routinely for clinical diagnosis, biomarkers in AD have been employed in large research trials for estimating risk, establishing a diagnosis of preclinical AD or mild cognitive impairment (MCI) due to AD pathology, measuring the progression of AD, and ultimately, for better understanding of the underlying pathophysiology. 6 In delirium, inflammatory, neurodegenerative, metabolic, and neurotransmitter-based biomarkers 1 have been investigated as potential research tools for risk stratification, diagnosis, monitoring, and prognosis, although none have yet been validated for clinical applications, such as diagnosis or monitoring of delirium.
Whereas AD is typically slowly progressive, delirium is a relatively rapid and dynamic syndrome in which biomarker levels may change abruptly in response to an acute stressor or stressors (surgery, infection, etc). For this reason, a useful model of biomarkers in delirium would include how biomarkers change over time, in order to consider those present before onset of disease (risk biomarker), those altered by disease (disease biomarker), and those reflecting the end product of a disease (outcome biomarker). 7 Due to the complex nature of delirium, with its myriad etiologies and protean manifestation, a model of shared delirium and dementia biomarkers would need to accommodate biomarkers that are common among multiple conditions.
Another important consideration for biomarkers of delirium and AD is the biofluid in which the biomarkers are measured. Cerebrospinal fluid (CSF) is thought to accurately represent brain changes, but there are challenges to collecting CSF, particularly in delirious patients, over multiple time points, and in large-scale studies. Despite these challenges, there is growing interest in using CSF biomarkers to better understand delirium pathophysiology. Blood-based biomarkers, which are more accessible during acute illness, may also be useful in delirium.
With the development of ultrasensitive immunoassays, protein biomarkers of neurodegeneration (tau) and axonal injury (neurofilament light, NfL) can now be measured in blood, although it remains to be determined whether these correlate with levels in the CSF, particularly in the setting of acute illness when most delirium occurs.
Much effort has been focused on protein biomarkers, which, while important, do not tell the whole picture. Other important avenues of future research include emerging blood-based biomarkers such as (1) exosomal microRNAs (miRs), which are small noncoding RNAs that modulate mRNA stability and posttranscriptional gene regulation that often become dysregulated in numerous conditions, including in the pathological process of AD, (2) novel neuronal injury biomarkers, such as those associated with endothelial damage and blood-brain barrier disruption, and (3) unbiased systems biology approaches (genomics, proteomics, lipidomics, and metabolomics). Ultimately, all of these approaches may be useful to explore shared mechanisms that contribute to delirium and AD.
| PROPOSED CONCEPTUAL MODEL
We propose a conceptual model ( Figure 1 ) illustrating how biomarker studies might advance our understanding of the interrelationship of delirium and AD. This model builds on the concept of vulnerability, the degree to which the brain adversely reacts to a stressor, resilience, which we describe as the ability of the brain to withstand and recover from the impact of stressors, 8 
Key points
• The interrelationship between delirium and Alzheimer disease (AD) is complex and poorly understood.
• Advances in cerebrospinal fluid (CSF) and blood-based biomarkers, including development of ultrasensitive immunoassays to measure protein biomarkers, and novel biomarkers such as exosomal microRNA may lead to discovery of biomarkers common to delirium and AD, potentially representing shared pathophysiology.
• We propose a conceptual model illustrating how biomarker studies might advance our understanding of the interrelationship of delirium and AD.
• Important issues in designing future biomarker studies include careful consideration of study design, sophisticated statistical analytic strategies, and standardization of assay platforms.
biomarkers, reflecting diverse processes that might include inflammation, alterations in neurotransmitter function, neuronal or microglial dysfunction, or acceleration of underlying chronic processes. Finally, outcome biomarkers indicating the end product of disease processes, such as neuronal injury or death, appear after delirium and may persist over the long term. We hypothesize that the occurrence of neuronal injury, as shown in our model, is critical to linking delirium and dementia.
| MECHANISMS AND PATHOPHYSIOLOGY AT THE INTERFACE OF DELIRIUM AND AD
Within the framework of our proposed conceptual model (Figure 1 ), we hypothesize that there are common baseline risk biomarkers and outcome biomarkers for delirium and AD and that these represent shared mechanisms and pathophysiology. Moreover, biomarkers of AD (which may be either risk markers or disease markers for AD depending on whether or not the AD is symptomatic) could also serve as risk biomarkers for delirium and thus identify individuals who are vulnerable in the face of stressors to developing delirium. Neuronal injury, as reflected by outcome biomarkers, may represent a final common pathway for disparate pathophysiologic processes that occur during acute delirium. These outcome markers for delirium may serve as risk markers for cognitive decline or AD following an episode of delirium. For example, systemic inflammation may lead to neuronal inflammation which then results in direct neuronal injury. 9 Thus, longitudinal studies are needed, 10 and we include this in our conceptual model. In the setting of underlying brain vulnerability, such as neurodegeneration or aging, systemic inflammation may lead to an exaggerated central inflammatory response, 11 and therefore potentially greater neuronal injury. It may also be possible that in the setting of AD pathology (which again may or may not be clinically symptomatic), neurons are more vulnerable to injury and cell death with even modest levels of neuroinflammation.
Whether neuronal injury from delirium can then subsequently initiate or accelerate AD pathology is not known, but we hypothesize that neuronal injury and death are critical steps connecting delirium and AD. range of insults including surgery, infections, hypoxia, metabolic abnormalities, stroke, drugs, or anesthetics, and these insults can vary in severity and duration. 2 Abnormal risk biomarkers (at baseline) of a vulnerable brain might reflect inflammation, oxidative stress, or chronic neurodegeneration present at basal level. 1 Abnormal biomarkers triggered by delirium might reflect inflammation, alterations in neurotransmitter function, neuronal or microglial dysfunction, or neuronal death, or acceleration of underlying chronic processes. As biomarkers become increasingly abnormal, delirium severity may increase as well. 3 Abnormal end product (ie, neuronal injury/cell death) biomarkers emerge in the convalescent phase when disease processes are sufficient during the acute phase to trigger neuronal injury. This model will accommodate multiple putative biomarkers. For example, anemia can still be integrated into our conceptual model, as a risk or disease marker that is contributory along the pathway to neuronal injury. AD, Alzheimer disease; ADRD, Alzheimer disease and related dementias; LTCD, long-term cognitive decline; MCI, mild cognitive impairment Therefore, biomarkers that reflect neuronal injury or death, in addition to biomarkers of AD, may yield important insight into the shared mechanisms between delirium and AD. Below, we review selected literature, with a focus on biomarkers reflecting neuronal injury that have been examined in both delirium and AD: (1) AD biomarkers and (2) biomarkers of neuronal injury. We also discuss important issues in designing future biomarker studies.
| AD BIOMARKERS AND DELIRIUM
Reduced CSF levels of amyloid β (Aβ)42 and elevated CSF levels of total tau (T-tau) and phospho-tau (P-tau) compared with controls have been established as an "AD-signature" for diagnosing cognitive impairment due to AD pathology. A recent meta-analysis of biomarker literature in AD and mild cognitive impairment (MCI) supports the association of this CSF AD-signature with AD and MCI. 12 Elevated levels of CSF T-tau have been described in traumatic brain injury, acute stroke, and other neurodegenerative conditions and likely reflect the intensity of neurodegeneration and disease progression.
Elevated CSF P-tau, a measure of the phosphorylation state of tau, appears to be more specific with AD. 13 Plasma levels of T-tau correlate poorly with CSF T-tau; however, plasma T-tau has been found to be associated with AD. To date, plasma findings have been less reproducible than those in CSF, at least using technology available up to this point. 13 Studies of AD biomarkers in delirium have been mixed. Several studies have associated the "CSF AD-signature" described above with delirium. Patients with postoperative delirium have a reduced CSF Aβ42/tau ratio, 14 and a recent study 15 found that patients without dementia who developed delirium had lower CSF Aβ42 levels, higher T-tau levels, and lower ratios of Aβ42 to T-tau and P-tau relative to those without delirium. In contrast, other studies did not find significant differences between preoperative CSF Abeta1-42, tau, and P-tau levels in participants who did and did not develop delirium. 16 Another AD-related biomarker that has been examined in delirium is apolipoprotein E (ApoE). Two different aspects of ApoE have been examined, the ApoE genotype, particularly the E4 allele, which has been strongly associated with AD, and absolute levels of the ApoE protein measured in plasma and CSF. The presence of an E4 allele of apolipoprotein E (ApoE) genotype has been associated with delirium in some studies, 17 but others did not observe this relationship. 18, 19 In meta-analyses, the ApoE E4 allele is associated with longer duration of delirium but not with delirium incidence. 17 Plasma ApoE levels are reduced in AD, 20 and it is hypothesized that ApoE plays a role in neuronal maintenance and repair. In patients with delirium, compared with AD, ApoE levels in CSF are even lower during delirium. This study observed no significant differences in ApoE in plasma between AD and delirium, nor did plasma and CSF ApoE levels correlate, suggesting that blood-based ApoE levels do not reflect brain dysfunction in delirium as well as they do in dementia. 21 Despite the conflicting findings, the potential role of ApoE in the relationship between delirium and dementia remains intriguing and worthy of further investigation. 24 or reduced in AD. 25 There were no differences in serum or plasma concentrations of NSE in patients with AD compared with controls in a number of studies. 12 NSE has also been examined in delirium, and overall, the findings are also mixed. Compared with participants with dementia, patients with delirium demonstrated lower levels of CSF NSE. 26 Delirium is associated with higher plasma NSE concentrations and mortality in critically ill patients. 27 A trend towards an association between persistently elevated plasma NSE levels and cognitive impairment at discharge in patients following cardiopulmonary bypass surgery 28 has been reported. Others found no significant difference in plasma NSE between delirium and control groups. injury. S100B serum levels are high during inflammation and after trauma or surgery. Among patients with AD, some studies report higher CSF levels of S100B in AD patients compared with controls, 30 and other studies report that S100B levels correlate with AD disease severity (Clinical Dementia Rating or Mini-Mental State Examination score). 24 Others have found higher CSF S100B levels in mild-tomoderate AD, which then decreased as the disease worsened. 31 There is significant literature examining the association of S100B
with delirium or outcomes after delirium. A number of studies have shown high plasma S100B levels in delirium 32, 33 or elevated CSF S100B levels measured at the time of hip fracture surgery in patients with delirium vs without delirium. 34 In keeping with these observations, a low concentration of S100B has been proposed to be used as a risk stratification marker to rule out delirium. 35 However, there are studies that did not detect any difference in plasma S100B levels in patients with and without cognitive impairment following cardiopulmonary bypass 27, 28 or found that CSF S100B levels were lower in patients with persistent delirium compared with those with probable AD. 26 A recent study of older hip fracture patients found that serum S100B was not associated with postoperative delirium, and although S100B was associated with cognitive decline or death in the first year after hip fracture, this was observed only in participants without perioperative delirium. 36 
| Glial fibrillary acidic protein
Glial fibrillary acidic protein (GFAP) is expressed by astrocytes and is used as a marker of astrocytosis in neurodegeneration. CSF concentration of GFAP has been shown to be elevated in AD, as well as in other neurodegenerative dementias 37 although other studies found no difference between AD and controls or between AD and other neurodegenerative conditions. 38 GFAP has not been demonstrated to be increased in delirium. 39 
| Brain-derived neurotrophic factor
Brain-derived neurotrophic factor (BDNF) functions to help support neuron survival and encourage the growth and differentiation of new neurons and synapses. Advanced age and low education have been associated with decreased serum BDNF levels, with the lowest levels in patients with AD, which also corresponded to the severity of cognitive impairment. 40 Others have observed that at early stages of AD, BDNF significantly increased in comparison with control groups although levels then declined in later stages of the disease, whereas another study found no change in BDNF. 41 BDNF has been found to be elevated in delirium in one study 27 and not elevated compared with controls in another study. 42 BDNF has not yet been studied as a resilience factor following an episode of delirium, which would correspond to its putative physiological role.
| Neurofilament light
Neurofilament light (NfL) is an intermediate filament protein that is expressed in neurons and believed to function primarily to provide structural support for the axon. 43 NfL is a general marker of neuronal injury and neurodegeneration and has also been detected in CSF and blood in multiple conditions including stroke, traumatic brain injury, multiple sclerosis, progressive supranuclear palsy, and frontotemporal dementia. In AD, serum NfL has been shown to be increased in AD and MCI patients compared with controls, with the highest serum levels in cases with positive amyloid PET scans. Serum NfL also correlated with poorer cognition and greater changes in neuroimaging. 44 In the CSF, NfL has been shown to predict neurodegeneration in older adults with very low AD risk. To date, NfL has not been examined in delirium.
| Ubiquitin carboxyl-terminal hydrolase L1
Ubiquitin carboxyl-terminal hydrolase (UCH-L1) is an important component of the ubiquitin-proteasome system (UPS), which functions to remove and degrade misfolded proteins. Impairment of the UPS results in the accumulation of misfolded proteins in the cell, and a decrease in UCH-L1 activity has associated with Parkinson disease and AD. UCH-L1 is found in neuronal cell bodies and is thought to be a highly specific marker of neuronal injury. UCH-L1 can be detected in CSF and serum in patients with traumatic brain injury, hypoxic-ischemic encephalopathy, and seizures. 45 Postmortem studies of brains from patients with sporadic AD show a downregulation of UCH-L1. 46 In TBI, UCH-L1 levels are increased within 1 hour. 47 Despite this potential promise as a neuronal injury biomarker, UCH-L1 has not been examined in any large dementia or delirium studies.
| MICRORNA AS POTENTIAL BIOMARKERS FOR DELIRIUM
MicroRNAs (miRs) are small noncoding RNAs that regulate the expression of mRNAs posttranscriptionally by inhibiting translation or degradation of their mRNA targets. Abnormal expression of miRNAs has been observed in diverse disease and altered physiological states. 48 While most miRNA are found intracellularly, circulating miRNAs or extracellular miRNAs have also been detected in different biofluids, including serum and plasma, and as such hold potential as biomarkers in aging and age-related disorders. 49 Circulating miRNAs are believed to be released and then protected from extracellular degradation through transport via exosomes (cell-derived extracellular vesicles), microvesicles, and other mechanisms. 48 Freely circulating diseasespecific or dysregulated miRs have been linked to pathogenic states. 49 In AD, miRNAs have been investigated in blood, serum, serum or plasma exosomes, and CSF and are both upregulated and downregu- Dysregulated miRs may influence gene transcription and protein expression and induce the spread of neurodegeneration. 50 The most consistently dysregulated miRNA markers for AD include miR-29b, miR-181c miR-15b, miR-146a, and miR-107 where uniform results have been observed in at least two independent studies. 51 In delirium, a recent pilot study 52 found that several miRs (miR146a, miR-125b, and miR-181c) known to modulate both neuronal and immune processes were examined among older patients who underwent total knee or hip replacement under spinal anesthesia.
Among patients who developed delirium, an upregulation of miR146a and miR-181c in CSF and downregulation of miR-146a in the serum were observed. Additionally, lower CSF miR-146a and lower CSF/serum miR-146a ratios were significantly associated with milder delirium severity. Taken together, these findings support a potential role for miRs as delirium risk, disease, or end product biomarkers.
miRNAs may likewise contribute to our understanding of shared delirium and dementia pathophysiology.
| DISCUSSION: RECOMMENDATIONS FOR FUTURE RESEARCH
Understanding the interface between delirium and AD is a highpriority focus of aging research. Biomarkers can play important roles in confirming diagnosis, measuring severity, and stratifying risk and may also be used to achieve a greater understanding of shared pathophysiology between delirium and AD and ultimately to find more effective treatment strategies. Biomarkers shared by both delirium and AD are potential "linkage" points whereby one condition may influence the other and could potentially explain, for example, how delirium accelerates the rate of cognitive decline in patients with AD.
Biomarkers of AD pathology and neuronal injury have been found in both delirium and AD (Table 1) ; however, the results across studies have been somewhat inconsistent. This in part may be due to study design, for example, the use of small sample sizes and cross-sectional designs. 53 For logistical reasons, CSF biomarker studies frequently rely on collecting CSF at the time of surgery, which can limit the patient population to those undergoing emergency surgery for acute hip fracture or other procedures performed under spinal anesthesia. Other methodologic issues include a lack of standardization of biomarker sample collection, processing, storage, and assays across labs or lack of quality control of assays within labs.
Specific issues should be considered when designing a study targeted towards biomarker discovery at the interface between delirium and AD ( static baseline risk markers and dynamic disease biomarkers that fluctuate over the course of the delirium episode and recovery period.
Careful consideration will need to be made for which time points delirium, cognitive function, and/or biomarkers will be measured in the study; the temporal relationship between biomarkers and the course of delirium-including the time before, during, and after the delirium episode-will be critical in understanding at which point(s) delirium may connect with dementia.
Carefully characterized clinical phenotypes are essential for effective biomarkers studies. Consistent use of validated delirium measures is a must, and both the occurrence and severity of delirium should be measured. Baseline cognitive function should be assessed and included in the analysis. If AD is used as inclusion criteria, how AD will be characterized in the study-ie, using a reference standard, clinical criteria, AD imaging or CSF biomarkers, an expert consensus panel,
or a combination thereof-should also be considered.
Biomarker discovery generally takes one of two general approaches-either hypothesis-derived screening of candidate biomarkers or broad-based laboratory screens. A particular advantage of multiplex assays is the identification of hundreds to thousands of proteins from a single sample across a wide assay dynamic range (pg/mL to ng/mL), with reasonable sensitivity, reproducibility, and high throughput. Examination of biomarkers over time is critical given the dynamic nature of delirium, as evidenced by the observation that IL-6 change over time in patients with delirium. 53, 54 In addition, due to the fluctuating and changing time course of delirium, ideally, biomarkers should be measured at multiple time points, to understand how biomarkers levels align with the course of delirium (eg, its onset, peak, duration, and resolution).
As delirium and AD often affect frail and medically complex older adults, attrition should be anticipated. Data analysis must consider possible flaws in the study design, confounding factors, and handling missing data. Lastly, standardization of assay platforms across laboratories and careful quality control within laboratories will allow for comparisons across studies.
| LIMITATIONS
Because this review is focused on biomarkers reflecting neuronal injury, a number of putative biomarkers shared between delirium and dementia were not discussed. It is likely that there are multiple mechanisms (and biomarkers) that are involved in the interface between delirium and dementia and unfortunately it is not possible to include all within this review. However, other putative biomarkers can still be integrated into our conceptual model, as risk or disease markers that are contributory along the pathway to neuronal injury.
For example, although the association of C-reactive protein and dementia has been mixed, 55 CRP has been shown, as defined in our model, to be a baseline (risk biomarker) and IL-6 to be an acute phase (disease biomarker) 54, 55 in delirium. Anemia and hypoproteinemia are considered to be precipitating factors for delirium; anemia, has also been associated with dementia. 56 Likewise, lowered levels of melatonin are associated with both MCI and delirium. 57 All of these could fit into our model as potential biomarkers reflecting brain vulnerability (ie, risk biomarkers).
| CONCLUSIONS
Delirium and AD have been closely linked epidemiologically, yet the pathophysiology underlying this relationship remains largely unknown and under-explored. Examining established biomarkers of AD in delirium studies, and emerging biomarkers of neuronal injury and microRNA in both studies of delirium and AD, may help to shed light on the shared complex pathophysiology underlying both syndromes.
Careful consideration of study design including eligibility criteria, rigorous measurement of delirium, AD, and the biomarkers of interest, and sophisticated analytic strategies to address confounding and attrition, will be important to achieve these goals. Through improved understanding of the pathophysiology of delirium and AD derived from such studies, interventions can be designed to reduce the impending epidemic of late-life cognitive impairment.
